Skip to content
Subscriber Only

Doctor Questions Theranos as His Employer Plans Lab-Test Pilot

  • Intermountain endocrinologist questions accuracy of blood work
  • Theranos says medical industry is resistant to change

A senior doctor at one of Theranos Inc.’s partners for a pilot program of its blood-testing technology questioned the accuracy of the startup’s tests, adding to mounting criticism of the Silicon Valley company.

Theranos rose to prominence because of its plan to compete with traditional testing labs by obtaining small samples using only a fingerprick’s worth of blood. The Wall Street Journal reported this week that the health-care startup, which the newspaper valued at $9 billion, has used the same technology as its competitors for most of its blood tests, undermining the company’s promotion of its technology as an advance in the health-care industry.